Valuation: Atrion Corporation

Market Cap 809M 708M 653M 603M 1.14B 77.2B 1.16B 7.8B 3.06B 38.03B 3.04B 2.97B 131B P/E 2022
28.6x
P/E 2023 34.4x
Enterprise Value 803M 703M 648M 599M 1.14B 76.63B 1.16B 7.74B 3.04B 37.75B 3.02B 2.95B 130B EV / Sales 2022
5.27x
EV / Sales 2023 3.9x
Free-Float
50.88%
Yield 2022
1.47%
Yield 2023 2.3%
3 years 274.98
Extreme 274.98
593
5 years 274.98
Extreme 274.98
805.62
10 years 274.98
Extreme 274.98
948.03
Manager TitleAgeSince
Corporate Secretary 53 2024-08-20
Director TitleAgeSince
Director/Board Member 53 2024-08-20
Date Insider Type Main position Quantity % Market Cap.
24-08-20Issuer sale

Director

151,205 8.5914%
24-08-20Issuer sale

Director

2,991 0.1699%
24-08-20Issuer sale

Chairman

150,927 8.5756%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-.--%-.--%-14.25% 809M
-0.50%-1.54%-29.69%-12.23% 164B
+1.80%+0.82%-6.19%-2.98% 107B
+0.32%+2.34%+2.06%+57.36% 59.04B
+0.79%-3.68%+40.47%+55.85% 51.72B
+0.72%-3.88%-14.40%-41.01% 41.87B
+0.47%-4.98% - - 34.7B
+2.66%+5.21%-12.29%-42.61% 28.93B
-1.10%-3.29%+54.30%-6.25% 24.99B
0.00%-1.01%-6.38%-3.16% 21.05B
Average +0.79%-0.93%+3.10%-1.03% 53.41B
Weighted average by Cap. +1.32%-0.93%-6.09%+1.54%

Financials

2022 2023
Net sales 184M 161M 148M 137M 259M 17.5B 264M 1.77B 695M 8.62B 689M 674M 29.64B 169M 148M 137M 126M 239M 16.15B 243M 1.63B 641M 7.96B 636M 622M 27.35B
Net income 35.01M 30.62M 28.24M 26.09M 49.5M 3.34B 50.33M 337M 133M 1.64B 131M 129M 5.65B 19.41M 16.98M 15.66M 14.46M 27.45M 1.85B 27.91M 187M 73.48M 912M 72.88M 71.3M 3.14B
Net Debt -25.21M -22.05M -20.34M -18.79M -35.65M -2.4B -36.25M -243M -95.44M -1.18B -94.66M -92.6M -4.07B -6.02M -5.26M -4.85M -4.48M -8.51M -574M -8.65M -57.99M -22.77M -283M -22.59M -22.1M -972M
Logo Atrion Corporation
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Employees
712
  1. Stock Market
  2. Stocks
  3. ATRI Stock